Effects of anticancer drugs on transcription factor–DNA interactions

Bibliography

• KOHN KW, JACKMAN J, O'CONNOR PM: Cell cycle control and cancer chemotherapy. J. Cell. Biochem. (1994) 54:440–452.
   PubMed Web of Science ®Google Scholar
• HURST HC: Transcription factors as drug targets in cancer. Eur. Cancer (1996) 32A:1857–1863.
   PubMed Web of Science ®Google Scholar
• HURLEY LH: DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer (2002) 2:188–200.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview summarisingthe present state of the field.
   Google Scholar
• WOYNAROWSKI JM: Targeting critical regions in genomic DNA with AT-specific anticancer drugs. Biochim. Biophys. Acta (2002) 1587:300–308.
   PubMedGoogle Scholar
• •Non-coding regions in DNA are critical to anticancer agents.
   Google Scholar
• KARAMOUZIS MV, GORGOULIS VG, PAPAVASSILIOU AG: Transcription factors and neoplasia: Vistas in novel drug design. Clin. Cancer Res. (2002) 8:949–961.
   PubMed Web of Science ®Google Scholar
• BERARDI P, RUSSELL M, EL-OSTA A, RIABOWOL K: Functional links between transcription, DNA repair and apoptosis. Mol Life Sci. (2004) 61:2173–2180.
   PubMedGoogle Scholar
• BROXTERMAN HJ, GEORGOPAPADAKOU NH: New cancer therapeutics: target-specific in, cytotoxics out? Drug Resist. Update (2004) 7:79–87.
   Google Scholar
• ADAMS J: The proteasome: a suitable antineoplastic target. Nat. Rev Cancer (2004) 4:349–360.
   PubMed Web of Science ®Google Scholar
• GNIAZDOWSKI M, CZYZ M: Transcription factors as targets of anticancer drugs. Acta Biochim. Poi (1999) 46:255–262.
   PubMedGoogle Scholar
• GNIAZDOWSKI M, DENNY WA, NELSON SM, CZYZ M: Transcription factors as targets for DNA-interacting drugs. Curr. Med. Chem. (2003) 10:909H924.
   Google Scholar
• ZEWAIL-FOOTE M, HURLEY LH: Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level. Anticancer Drug Des. (1999) 14:1–9.
   PubMedGoogle Scholar
• VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291:1304–1351.
   PubMed Web of Science ®Google Scholar
• ••The paper became a classic on itspublication.
   Google Scholar
• ORPHANIDES G, LAGRANGE T, REINBERG D: The general transcription factors of RNA polymerase II. Gene Develop. (1996) 10:2657–2683.
   PubMed Web of Science ®Google Scholar
• PATIGLOU G, BURLEY SK: Eukaryotic transcription factor-DNA complexes. Ann. Rev Biophys. Biomol Struct. (1997) 26:289H325.
   Google Scholar
• GOLDBERG IH, REICH E, RABINOWITZ M: Inhibition of RNA polymerase reactions by actinomycin and proflavine. Nature (1963) 199:44–46.
   Google Scholar
• ••Classic paper presenting DNA-interactingdrugs as inhibitors of transcription.
   Google Scholar
• GALE EF, CUNDLIFFE E, REYNOLDS PE, RICHMOND MH, WARING MJ: Inhibitors of nucleic acid synthesis. In: The Molecular Bash of Antibiotic Action (1981) pp. 258–401, WILEY NY. The paper summarising first two decades of research of DNA-interacting ligands - essential facts on interactions and principles of the methods that are now in handbooks.
   Google Scholar
• BAGULEY BC: DNA intercalating antiHtumour agents. Anticancer Drug Des. (1991) 6:1–35.
   PubMedGoogle Scholar
• BRANA MF, CACHO M, GRADILLAS A, DE PASCUAL-TERESA B, RAMOS A: Intercalators as anticancer drugs. Curr. Pharmaceut. Design (2001) 7:1745–1780.
   PubMed Web of Science ®Google Scholar
• •Recent review on therapeutically Important intercalators.
   Google Scholar
• GNIAZDOWSKI M, CERA C: The effects of DNA covalent adducts on in vitro transcription. Chem. Rev (1996) 96:619–634.
   PubMedGoogle Scholar
• WELCH JJ, RAUSCHER III FJ, BEERMAN TA: Targeting DNA-binding drugs to sequence-specific transcription factor-DNA complexes. J. Biol. Chem. (1994) 269:31051–31058.
   PubMed Web of Science ®Google Scholar
• •One of the basic papers from this laboratory on the problem, bringing an extensive discussion.
   Google Scholar
• BELLORINI M, MONCOLLIN V, D'INCALCI M, MONGELLI N, MANTOVANI R: Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Adds Res. (1995) 23:1657–1663.
   PubMed Web of Science ®Google Scholar
• BRUICE TC, SENGUPTA D, BLASKO A, CHIANG S-Y, BEERMAN TA: A microgonotropen branched decaaza decabutylamine and its DNA and DNA/transcription factor interactions. Bioorg. Med. Chem. (1997) 5:685–692.
   PubMedGoogle Scholar
• BONFANTI M, LA VALLE E, FARO J-MFS et al.: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. (1999) 14:179H186.
   Google Scholar
• SUN D, HURLEY LH: TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin. Chem. Biol. (1995) 2:457H469.
   Google Scholar
• •How a transcription factor induces cell to suicide pathways.
   Google Scholar
• VICHI P, COIN F, RENAUD J-P et al: Cisplatin- and UV-damaged DNA lure the basal transcription Factor IID/TBP. EMBO J. (1997) 16:7444–7456.
   PubMed Web of Science ®Google Scholar
• •Presents evidence as to how the modified DNA may trap proteins.
   Google Scholar
• JUNG Y, MIKATA Y, LIPPARD SJ: Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA. J. Biol. Chem. (2001) 276:43589H43596.
   Google Scholar
• WEI M, COHEN SM, SILVERMAN AP, LIPPARD SJ: Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. Biol. Chem. (2001) 276:38774–38780.
   Google Scholar
• •Affinity of proteins to cisplatin adducts.
   Google Scholar
• CZYZ M, GNIAZDOWSKI M: Actinomycin D specifically inhibits the interaction between transcription factor Spl and its binding site. Acta Biochim. Poi (1998) 45:67–73.
   PubMed Web of Science ®Google Scholar
• BIANCHI N, PASSADORE M, RUTIGLIANO C, FERIOTTO G, MISCHIATI C, GAMBARI R: Targeting of the Spl binding sites of HIV-1 long terminal repeat with chromomycin. Biochem. Pharmacol (1996) 52:1489–1498.
   PubMed Web of Science ®Google Scholar
• CHIANG S-Y, AZIZKHAN JC, BEERMAN TA: A comparison of DNA-binding drugs as inhibitors of E2F1 and Spl-DNA complexes and associated gene expression. Biochemistry (1998) 37:3109–3115.
   PubMedGoogle Scholar
• PORTUGAL J, MARTIN B, VAQUERO A, FERRER N, VILLAMARIN S, PRIEBE W: Analysis of the effects of daunorubicin and WP 631 on transcription. Curr. Med. Chem. (2001) 8:1–8.
   PubMed Web of Science ®Google Scholar
• SZULAWSKA A, GNIAZDOWSKI M, CZYZ M: Sequence specificity of formaldehyde-mediated covalent binding of anthacycline derivatives to DNA. Biochem. Pharmacol (2005) 69:7–18.
   PubMedGoogle Scholar
• SUN D, HURLEY LH: Binding of Spl to the 21-bp repeat region of 5V40 DNA: effect of intrinsic and drug-induced DNA bending between GC boxes. Gene (1994) 149:165–172.
   PubMedGoogle Scholar
• MACLEOD MC, POWELL KL, KUZMIN VA, KOLBANOVSKIY A, GEACINTOV NE: Interference of benzolalpyrene diol epoxide-deoxyguanosine adducts in a GC box with binding of the transcription factor Spl. Mol. Carcinogen. (1996) 16:44–52.
   PubMed Web of Science ®Google Scholar
• •Carcinogens may also trap regulatory proteins.
   Google Scholar
• BROGGINI M, D'INCALCI M: Modulation of transcription factor-DNA interactions by anticancer drugs. Anticancer Drug Des. (1994) 9.373–387.
   PubMedGoogle Scholar
• ••One of the series of papers from this groupsystematically exploring the problem.
   Google Scholar
• TAYLOR A, WEBSTER KA, GUSTAFSON TA, KEDES L: The anti-cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation. Mol. Cell. Biochem. (1997) 169:61–72.
   PubMedGoogle Scholar
• HO SN, BOYER SH, SCHREIBER SL, DANISHEFSKY SJ, CRABTREE GR: Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: A paradigm for the development of transcriptional antagonists. Proc. Natl. Acad. Sci. USA (1994) 91:9203H9207.
   Google Scholar
• MACLEOD MC, POWELL KL, TRAN N: Binding of the transcription factor, Spl, to non-target sites in DNA modified by benzolalpyrene diol epoxide. Carcinogenesis (1995) 16:975–983.
   PubMed Web of Science ®Google Scholar
• STUHLMEIER KM: Effects of quinacrine on endothelial cell morphology and transcription factor-DNA interactions. Biochim. Biophys. Acta (2000) 1524:57–65.
   Web of Science ®Google Scholar
• CHIANG S-Y, BRUICE TC, AZIZKHAN JC, GAWRON L, BEERMAN TA: Targeting E2F1-DNA complex with microgonotropen DNA binding agents. Proc. Nati Acad. Sci. USA (1997) 94:2811–2816.
   PubMedGoogle Scholar
• JOHNSON DG, COLEMAN A, POWELL KL, MACLEOD MC: High-affinity binding of the cell cycleHregulated transcription factors E2F1 and E2f4 to benzolalpyrene diol epoxide-DNA adducts. Mol. Carcinogen. (1997) 20:216–223.
   PubMed Web of Science ®Google Scholar
• DICKINSON LE, TRAUGER JW, BAIRD EE, DERVAN PB, GRAVES BJ, GOTTESFELD JM: Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-KB, and DNA by a designed DNA-binding ligand. J. Biol. Chem. (1999) 274:12765–12773.
   PubMedGoogle Scholar
• CHIANG SY, BURLI RW, BENZ CC et al.: Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem. (2000) 275:24246–24254.
   PubMed Web of Science ®Google Scholar
• WURTZ NR, POMERANTZ JL, BALTIMORE D, DERVAN PB: Inhibition of DNA binding by NF-kappa B with pyrrole-imidazole polyamides. Biochemistry (2002) 41:7604H7609.
   Google Scholar
• ••One of the series of papers from this groupon polyamides of high sequence selectivity.
   Google Scholar
• TURNER PR, DENNY WA: The genome as a drug target: Sequence specific minor groove binding ligands. Curr. Drug Targets (2000) 1:1–14.
   PubMedGoogle Scholar
• WHITE CM, HEIDENREICH 0, NORDHEIM A, BEERMAN TA: Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target. Biochemistry (2000) 39:12262–12273.
   PubMed Web of Science ®Google Scholar
• WANG YD, DZIEGIELEWSKI J, WURTZ NR, DZIEGIELEWSKA B, DERVAN PB, BEERMAN TA: DNA crosslinking and biological activity of a hairpin polyamide chlorambucil conjugate. Nucleic Acids Res. (2003) 31:1208–1215.
   PubMed Web of Science ®Google Scholar
• ••See comment to [44].
   Google Scholar
• GIESEG MA, DE BOCK C, TURNER PM, FERGUSON LR, DENNY WA: The effect of DNA-alkylating agents on gene expression from two integrated reporter genes in the cell line EMT6.Anticancer Drugs (2002) 13:271–280.
   PubMedGoogle Scholar
• DENNY WA, BAGULEY BC: Dual topoisomerase I/II inhibitors in cancer therapy. Curl: Top. Med. Chem. (2003) 3:339–353.
   PubMed Web of Science ®Google Scholar
• VAN DYKE MW, DERVAN PB: Methidiumpropyl-EDTA.Fe(II) and DNase I footprinting report different small molecule binding site sizes on DNA. Nucleic Acids Res. (1983) 11:5555–5567.
   Google Scholar
• •Classic paper demonstrating the foot-printing techniques.
   Google Scholar
• WAKELIN LPG, ATWELL GJ, REWCASTLE GW, DENNY WA: Relationships between DNA-binding kinetics and biological activity for the 9Haminoacridine-4-carboxamide class of antitumor agents. J. Med. Chem. (1987) 30:855–861.
   PubMedGoogle Scholar
• WHITE RJ, PHILLIPS DR: SequenceHdependent termination of bacteriophage Ti transcription in vitro by DNA-binding drugs. Biochemistry (1989) 28:4277–4283.
   PubMedGoogle Scholar
• LENG F, CHAIRES JB, WARING MJ: Energetics of echinomycin binding to DNA. Nucleic Acids Res. (2003) 31:6191H6197.
   Google Scholar
• FOX KR, WEBSTER R, PHELPS RJ, FOKT I, PRIEBE W: Sequence selective binding of bis-daunorubicin WP631 to DNA Eur. Biochem. (2004) 271:3556H3566.
   Google Scholar
• CHAIRES JB, PRIEBE W, GRAVES DE, BURKE TG: Dissection of the free energy of anthracycline antibiotic binding to DNA: Electrostatic contributions. J. Am. Chem. Soc. (1993) 115:5360–5364.
   Google Scholar
• BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Curl: Med. Chem. (2000) 7:39–58.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI S, BHATTACHARYYA D, DASGUPTA D: Structural basis of DNA recognition by anticancer antibiotics, chromomycin A3, and mithramycin: roles of minor groove width and ligand flexibility. Biopolymers (2001) 56:85–95.
   Web of Science ®Google Scholar
• KOPKA ML, GOODSELL DS, HAN GW, CHIU TK, LOWN JW, DICKERSON RE: Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin toCATGGCC A-T-G. Structure (1997) 5:1033–1046.
   PubMed Web of Science ®Google Scholar
• •Very nice structural biology study showing how imidazole ring changes reading of the minor groove by the drug molecule.
   Google Scholar
• CHEN X, RAMAKRISHNAN B, SUNDARALIN GAM M: Crystal structures of the side-by-side binding of distamycin to AT-containing DNA octamers cl(ICITACIC) and d(ICATATIC). Moi Bia (1997) 267:1157–1170.
   PubMedGoogle Scholar
• KERS I, DERVAN PB: Search for the optimal linker in tandem hairpin polyamides. Bioorg. Med. Chem. (2002) 10:3339–3349.
   PubMedGoogle Scholar
• GOPAL YNV, VAN DYKE MW: Combinatorial determination of sequence specificity for nanomolar DNA-binding hairpin polyamides. Biochemistry (2003) 42:6891–6903.
   PubMedGoogle Scholar
• WEYERMANN P, DERVAN, PB: Recognition of ten base pairs of DNA by head-to-head hairpin dimers. J. Am. Chem. Soc. (2002) 124:6872–6878.
   PubMed Web of Science ®Google Scholar
• DICKINSON LA, TRAUGER JW, BAIRD EE, GHAZAL P, DERVAN PB, GOTTESFELD JM: Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides. Biochemistry (1999) 38:10801–10807.
   PubMed Web of Science ®Google Scholar
• BREMER RE, WURTZ NR, SZEWCZYK JW, DERVAN PB: Inhibition of major groove DNA binding bZIP proteins by positive patch polyamides. Bioorg. Med. Chem. (2001) 9:2093–2103.
   PubMedGoogle Scholar
• DICKINSON LA, GULIZIA RJ, TRAUGER JW et al.: Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Natl. Acad. Sci. USA (1998) 95:12890–12895.
   PubMed Web of Science ®Google Scholar
• BROGGINI M, COLEY HM, MONGELLI N et al: DNA sequenceHspecific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res. (1995) 23:81–87.
   PubMed Web of Science ®Google Scholar
• SMAILL JB, FAN J-Y, PAPA PV, O'CONNOR CJ, DENNY WA: Mono- and difunctional nitrogen mustard analogues of the DNA minor groove binder pibenzimol. Synthesis, cytotoxicity and interaction with DNA. Anticancer Drug Des. (1998) 13:221–242.
   PubMedGoogle Scholar
• HURLEY LH, RECK T, THURSTON DE, HERTZBERG RP et al.: Pyrrolo [1,4] benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem. Res. Toxicol. (1988) 1:258–268.
   PubMed Web of Science ®Google Scholar
• TOMASZ M, PALOM Y: The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol. Ther. (1997) 76:73–87.
   PubMed Web of Science ®Google Scholar
• •A review. According to our knowledge, surprisingly mitomycin adducts were not assayed for effects on transcription factor-DNA interactions.
   Google Scholar
• TAATJES DJ, FENICK DJ, KOCH TH: Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol. (1999) 12:588–596.
   PubMed Web of Science ®Google Scholar
• PRASEUTH D, GUIEYSSE AL, HELENE C: Triple helix formation and the antigene strategy for sequenceHspecific control of gene expression. Biochim. Biophys. Acta (1999) 1489:181–206.
   PubMed Web of Science ®Google Scholar
• ••A review on antigene strategy from thegroup that has contributed much to this field.
   Google Scholar
• NIELSEN PE: Peptide nucleic acids: On the road to new gene therapeutic drugs. Pharmacol. Toxicol. (2000) 86:3–7.
   PubMedGoogle Scholar
• ••The basic concept, presented by oneof its creators.
   Google Scholar
• FARIA M, GIOVANNANGELI C: Triplex-forming molecules: from concepts to applications. ./. Gene Med. (2001) 3:299H310.
   Google Scholar
• YANG DC, ELLIOTT RL, HEAD JF: Gene targets of antisense therapies in breast cancer. Expert Opin. Ther. Targets (2002) 6:375–385.
   PubMedGoogle Scholar
• UHLMANN E: Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. Chem. Biol. (1998) 379:1045–1052.
   Google Scholar
• VESTER B, WENGEL J: LNA (Locked Nucleic Acid): High-affinity targeting of complementary RNA and DNA. Biochemistry (2004) 43:13233H13241.
   Google Scholar
• •Recent review on LNA.
   Google Scholar
• GUIEYSSE AL, PRASEUTH D, GIOVANNANGELI C, ASSELINE U, HELENE C: Psoralen adducts induced by triplex-forming oligonucleotides are refractory to repair in HeLa cells. Moi Biol. (2000) 296:373–383.
   Google Scholar
• GIRAUD-PANIS M-J, LENG M: Transplatin-modified oligonucleotides as modulators of gene expression. Pharmacol. Ther. (2000) 85:175–181.
   PubMedGoogle Scholar
• EHLEY JA, MELANDER C, HERMAN D et al: Promoter scanning for transcription inhibition with DNA-binding polyamides. Mol. Cell. Biol. (2002) 22:1723–1733.
   PubMedGoogle Scholar
• ABDELRAHIM M, SMITH III R, BURGHARDT R et al: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. (2004) 64:6740–6749.
   PubMed Web of Science ®Google Scholar
• MANSILLA S, PRIEBE W, PORTUGAL J: Spl-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry (2004) 43:7584H7592.
   Google Scholar
• •Recent paper conforming Spl inhibition by bis-anthracycline in the cell.
   Google Scholar
• DREDGE K, DALGLEISH AG, MARRIOTT JB: Recent developments in antiangiogenic therapy. Expert Opin. Bid. Ther. (2002) 2:953–966.
   PubMed Web of Science ®Google Scholar
• STEPHENS TD, BUNDE CJW, FILLMORE BJ: Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol (2000) 59:1489–1499.
   PubMedGoogle Scholar
• •An interesting concept, yet to be experimentally approached.
   Google Scholar
• DRUCKER L, UZIEL 0, TOHAMI T et al.: Thalidomide down-regulates transcript levels of GC-rich promoter genes in mutlipe myeloma. Mol. Pharmacol (2003) 64:415–420.
   Google Scholar
• KARIN M, CAO Y, GRETEN FR, LI ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev Cancer (2002) 2:301–310.
   PubMed Web of Science ®Google Scholar
• BURD JF, WARTELL RM, DODGSON JB, WELLS RD: Transmission of stability (telestability) in deoxyribonucleic acids. Physical and enzymatic studies on the duplex block polymer d(C15A15)-d(T15G15). Bid. Chem. (1975) 250:5109–5113.
   Google Scholar
• ••Classic paper, seemingly somewhatforgotten, on the transmission of conformational change along the double helix.
   Google Scholar
• WHITE CM, SATZ AL, BRUICE TC, BEERMAN TA: Inhibition of transcription factor-DNA complexes and gene expression by a microgonotropen. Proc. Natl. Acad. Sci. USA (2001) 98:10590–10595.
   PubMedGoogle Scholar
• KLEIN C, VASSILEV LT: Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer (2004) 91:1415–1419.
   PubMed Web of Science ®Google Scholar
• ••Emerging target: protein-proteinInteractions.
   Google Scholar
• DARNELL JE Jr: Transcription factors targets for cancer therapy. Nat. Rev Cancer (2002) 2:740–749.
   PubMedGoogle Scholar
• •Selection of two transcription factors which, according to the author, may be critical.
   Google Scholar
• KANOH J, ISHIKAWA F. Composition and conservation of the telomeric complex. Mol. Life Sri. (2003) 60:2295–302.
   PubMedGoogle Scholar
• REZLER EM, BEARSS DJ, HURLEY LH. Telomeres and telomerases as drug targets. Curr. Opin. Pharmacol (2002) 2:415–23.
   PubMed Web of Science ®Google Scholar
• HARRISON RJ, CUESTA J, CHESSARI G et al: Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J. Med. Chem. (2003) 46:4463–4476.
   PubMed Web of Science ®Google Scholar
• MANO Y, SHIMIZU T, TANUMA S, TAKEDA, K. Synergistic down-regulation of telomerase activity and hTERT mRNA expression by combination of retinoic acid and GM-CSF in human myeloblastic leukemia ML-1 cells. Anti-Cancer Res. (2000) 20:1649–1652.
   Google Scholar
• TRIMMER EE, ZAMBLE DB, LIPPARD SJ, ESSIGMANN JM: Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry (1998) 37:352–362.
   PubMed Web of Science ®Google Scholar
• WETZEL CC, BERBERICH SJ: p53 binds to cisplatin-damaged DNA. Biochim. Biophys. Acta (2001) 1517:392H397.
   Google Scholar
• KASPARKOVA J, FOJTA M, FARRELL N, BRABEC V: Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Adds Res. (2004) 32:5546–5552.
   PubMedGoogle Scholar
• TURCHI JJ, LI M, HENKELS KM: Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry (1996) 35:2992–3000.
   PubMedGoogle Scholar
• YARNELL AT, OH S, REINBERG D, LIPPARD SJ: Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J. Biol. Chem. (2001) 276:25736–25741.
   PubMed Web of Science ®Google Scholar
• ZLATANOVA J, YANEVA J, LEUBA SH: Proteins that specifically recognize cisplatinHdamaged DNA: a clue to anticancer activity of cisplatin. FASEB J. (1998) 12:791–799.
   PubMed Web of Science ®Google Scholar
• LEE SJ, HURLEY LH: A thymine: thymine mismatch enhances the pluramycin alkylation site downstream of the TBPHTATA box complex. I Am. Chem. Soc. (1999) 121:8971–8977.
   Google Scholar
• ZEWAIL-FOOTE M, HURLEY LH: Differential rates of reversibility of ecteinascidin 743 - DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc. (2001) 123:6485–6495.
   PubMed Web of Science ®Google Scholar
• MARCO E, GARCIA-NIETO R, MENDIETA J, MANZANARES I, CUEVAS C, GAGO F: A 3A (ET743)HDNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. I Med. Chem. (2002) 45:871–880.
   PubMed Web of Science ®Google Scholar
• WANG YD, DZIEGIELEWSKI J, CHANG AY, DERVAN PB, BEERMAN TA: Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate. J. Bid. Chem. (2002) 277:42431–42437.
   PubMedGoogle Scholar
• BELITSKY JM, LESLIE SJ, ARORA PS, BEERMAN TA, DERVAN PB: Cellular uptake of N-methylpyrrole/ NHmethylimidazole polyamide-dye conjugates. Bioorg. Med. Chem. (2002) 10:3313–3318.
   PubMedGoogle Scholar
• BARALDI PG, BOVERO A, FRUTTAROLO F et al : DNA minor groove binders as potential antitumor and antimicrobial agents. Med. Res. Rev (2004) 24:475–528.
   PubMed Web of Science ®Google Scholar
• •Recent review on the DNA minor groove reading drugs.
   Google Scholar
• CUTTS SM, PARSONS PG, STURM RA, PHILLIPS DR: Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Bid. Chem. (1996) 271:5422–5429.
   PubMedGoogle Scholar
• GRIGORIEV M, PRASEUTH D, ROBIN P et al: A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NFKB binding to interleukin-2 receptor a-regulatory sequence../. Bid. Chem. (1992) 267:3389–3395.
   PubMed Web of Science ®Google Scholar
• CRINELLI R, BIANCHI M, GENTILINI L et al: Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. Nucleic Adds Res. (2004) 32:1874H1885.
   Google Scholar
• PARK YG, NESTEROVA M, AGRAWAL S, CHO-CHUNG YS: Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide, gene-specific inhibition of tumor growth. Biol. Chem. (1999) 274:1573–1580.
   Google Scholar
• YANG X, FENNEWALD S, LUXON BA, ARONSON J, HERZOG NK, GORENSTEIN DG: Aptamers containing thymidine 3'-0-phosphorodithioates: Synthesis and binding to nuclear factor-KB. Bioorg. Med. Chem. Lett. (1999) 9:3357–3362.
   PubMed Web of Science ®Google Scholar
• MISCHIATI C, BORGATTI M, BIANCHI N et al: Interaction of the human NF-x13 p52 transcription factor with DNA-PNA hybrids mimicking the NF-x13 binding sites of the human immunodeficiency virus Type 1 promoter. J. Biol. Chem. (1999) 274:33114–33122.
   PubMed Web of Science ®Google Scholar
• BORGATTI M, LAMPRONTI I, ROMANELLI A et al: Transcription factor decoy molecules based on a peptide nucleic acid (PNA) -DNA chimera mimicking SP1 binding sites. J. Biol. Chem. (2003) 278:7500–7509.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, KANDIMALLA ER: Antisense therapeutics: is it as simple as complementary base recognition. Mol Med. Today (2000) 6:72–81.
   PubMedGoogle Scholar
• WAGNER AH, KRZESZ R, GAO D, SCHROEDER CH, CATTARUZZA M, HECKER M: Decoy oligodeoxynucleotide characterization of transcription factors controlling endothelin-B receptor expression in vascular smooth muscle cells. Mol Pharmacol (2000) 58:1333–1340.
   PubMedGoogle Scholar
• COOPER JAD, PARKS JM, CARCELEN R, KAHLON SS, SHEFFIELD M, CULBRETH R: Attenuation of interleukin-8 production by inhibiting nuclear factor-KB translocation using decoy oligonucleotides. Biochem. Pharmacol (2000) 59:605–613.
   PubMedGoogle Scholar
• LAMBERTINI E, PENOLAZZI L, AGUIARI G et al: Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor a gene. Biochem.Biophys. Res. Comm. (2002) 292:761–770.
   PubMedGoogle Scholar
• CHATTERJEE S, ZAMAN K, RYU H, CONFORTO A, RATAN RR: Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann. Neurol (2001) 49:345–354.
   PubMed Web of Science ®Google Scholar
• RINK SM, YAREMA KJ, SOLOMON MS et al.: Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Biochemistry (1996) 93:15063–15068.
   Google Scholar
• BECKERBAUER L, TEPEE, CULLISON J, REEVES R, WILLIAMS RM: FR900482 class of antiHtumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem. Biol. (2000) 7:805–812.
   PubMed Web of Science ®Google Scholar
• SAMUEL SK, SPENCER VA, BAJNO L et al.: in situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. Cancer Res. (1998) 58:3004–3008.
   PubMed Web of Science ®Google Scholar
• PALANKI MSS: Inhibitors of AP-1 and NF-x13 mediated transcriptional activation: Therapeutic potential in autoimmune diseases and structural diversity. Curl: Med. Chem. (2002) 9:219–227.
   Google Scholar
• IJAZ T, TRAN P, RUPARELIA KC, TEESDALE-SPITTLE PH, ORR S, PATTERSON LH: Anthraquinone-peptides as inhibitors of AP-1 transcription factor. Bioorg. Med. Chem. Lett. (2001) 11:351-353.ZHANG Z, CHALTIN P, VAN AERSCHOT A et al.: New dsDNA binding unnatural oligopeptides with pyrimidine selectivity. Bioorg. Med. Chem. (2002) 10:3401-3413.Selection of oligopeptides with unnatural amino acids binding DNA.
   Google Scholar
• ZHANG Z, CHALTIN P, VAN AERSCHOT A et al.: New dsDNA binding unnatural oligopeptides with pyrimidine selectivity. Bioorg. Med. Chem. (2002) 10:3401–3413.
   Google Scholar
• • Selection of oligopeptides with unnatural amino acids binding DNA.
   Google Scholar